12:00 Thu 01 Jun 2017
ValiRx PLC - Yorkville CLN Conversion
ValiRx Plc
("
Yorkville CLN Conversion
Yorkville has elected to convert
Application for the 10,453,630 ordinary shares will be made to the
Following the issue of equity above the Company's issued share capital will comprise of 143,809,744 ordinary shares.
This announcement is inside information for the purposes of Article 7 of Regulation 596/2014.
For more information, please contact:
|
Tel: +44 (0) 20 3008 4416 |
Dr |
Tel: +44 (0) 20 3008 4416 |
|
Tel: +44 (0) 7879 458 364 |
|
Tel: +44 (0) 20 7213 0880 |
|
|
|
Tel: +44 (0) 207 382 8300 |
|
|
Notes for Editors
The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.
Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in
The Company listed on the AIM market of the
This information is provided by RNS
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE